ES2193248T3 - Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea. - Google Patents

Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea.

Info

Publication number
ES2193248T3
ES2193248T3 ES96922001T ES96922001T ES2193248T3 ES 2193248 T3 ES2193248 T3 ES 2193248T3 ES 96922001 T ES96922001 T ES 96922001T ES 96922001 T ES96922001 T ES 96922001T ES 2193248 T3 ES2193248 T3 ES 2193248T3
Authority
ES
Spain
Prior art keywords
osea
matrix
treatment
disulfosustituidas
antraquinonas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96922001T
Other languages
English (en)
Inventor
Dino Benetti
Ruggero Aloisi
Giuseppe Guainai
Sergio Rosini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H GEN BV
Original Assignee
H GEN BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H GEN BV filed Critical H GEN BV
Application granted granted Critical
Publication of ES2193248T3 publication Critical patent/ES2193248T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

EL USO DE LOS COMPUESTOS DE LA FORMULA (I), CUYOS GRUPOS SE DEFINEN EN LA PUBLICACION, EN LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE PATOLOGIAS EN LAS QUE SE PRODUCE EROSION DE LA MATRIZ CARTILAGINOSA Y OSEA.
ES96922001T 1995-06-23 1996-06-17 Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea. Expired - Lifetime ES2193248T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI001357A IT1276781B1 (it) 1995-06-23 1995-06-23 Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie

Publications (1)

Publication Number Publication Date
ES2193248T3 true ES2193248T3 (es) 2003-11-01

Family

ID=11371864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96922001T Expired - Lifetime ES2193248T3 (es) 1995-06-23 1996-06-17 Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea.

Country Status (16)

Country Link
US (1) US5856358A (es)
EP (1) EP0833626B1 (es)
JP (1) JP3307650B2 (es)
AT (1) ATE233553T1 (es)
AU (1) AU6303996A (es)
CA (1) CA2225277A1 (es)
CZ (1) CZ293326B6 (es)
DE (1) DE69626514T2 (es)
DK (1) DK0833626T3 (es)
ES (1) ES2193248T3 (es)
IT (1) IT1276781B1 (es)
MX (1) MX9800049A (es)
PT (1) PT833626E (es)
RU (1) RU2202534C2 (es)
SK (1) SK281853B6 (es)
WO (1) WO1997000675A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608133D0 (en) * 1996-04-19 1996-06-26 Gemini International Holdings Diagnostic method and apparatus
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
US6117869A (en) * 1998-08-04 2000-09-12 Warner-Lambert Company Compounds for and methods of inhibiting matrix metalloproteinases
US6174903B1 (en) 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
US6610750B1 (en) * 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
AUPR229600A0 (en) * 2000-12-22 2001-01-25 Commonwealth Scientific And Industrial Research Organisation New oxygen scavenging compositions
US6600057B2 (en) * 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US8790714B2 (en) 2007-08-03 2014-07-29 Nucitec, S.A. De C.V. Compositions and methods for treatment and prevention of osteoarthritis
CA2781706A1 (en) * 2009-11-24 2011-06-03 The Ohio State University Transcription factor inhibitors and related compositions, formulations and methods
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2025954A (en) * 1978-07-21 1980-01-30 Ciba Geigy Ag Anthraquinone Sulphonamides
IT1244773B (it) * 1991-03-12 1994-08-08 Gentili Ist Spa N-(4,5-diidrossi-e 4,5,8-triidrossi-9,10-diidro-9,10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari

Also Published As

Publication number Publication date
SK281853B6 (sk) 2001-08-06
CZ419397A3 (cs) 1998-07-15
SK176097A3 (en) 1998-06-03
WO1997000675A1 (en) 1997-01-09
DE69626514T2 (de) 2003-12-24
EP0833626B1 (en) 2003-03-05
ITMI951357A1 (it) 1996-12-23
IT1276781B1 (it) 1997-11-03
EP0833626A1 (en) 1998-04-08
DE69626514D1 (de) 2003-04-10
AU6303996A (en) 1997-01-22
JP3307650B2 (ja) 2002-07-24
CZ293326B6 (cs) 2004-04-14
US5856358A (en) 1999-01-05
MX9800049A (es) 1998-11-30
JPH11509186A (ja) 1999-08-17
PT833626E (pt) 2003-07-31
ATE233553T1 (de) 2003-03-15
CA2225277A1 (en) 1997-01-09
DK0833626T3 (da) 2003-06-30
RU2202534C2 (ru) 2003-04-20
ITMI951357A0 (it) 1995-06-23

Similar Documents

Publication Publication Date Title
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
MX9306986A (es) Composiciones farmaceuticas a base de taxoides.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2191286T3 (es) Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
ATE233274T1 (de) Oxyiminopregnancarbolactone
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
AR003107A1 (es) Derivados de vitamina d para uso dermatologico, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.